Benralizumab Trial Correction

The author correction addresses data errors in a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome. The correction addresses data errors in a randomized, placebo-controlled phase 3 trial of benralizumab for hypereosinophilic syndrome. The correction addresses data errors in a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome. The HTML and PDF versions of the article have been corrected. The article reports corrections to data errors in a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome. The article is an author correction for a randomized, placebo-controlled phase 3 trial of benralizumab versus placebo for hypereosinophilic syndrome. The original benralizumab study was published in Nature Medicine on March 31, 2026.